MedTrace Logo

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

NCT06644118 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-11-08

No results posted yet for this study

Summary

This clinical trial aims to characterize the safety of OL-101 and establish the recommended dose for future research and to evaluate the efficacy of OL-101 (Dose expansion).

Conditions

Interventions

BIOLOGICAL

OL-101 infusion

OL-101 infusion will be administered to patients via IV infusion at the assigned dose.

Sponsors & Collaborators

  • Overland Therapeutics

    collaborator UNKNOWN

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-23
Primary Completion
2027-10-31
Completion
2028-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06644118 on ClinicalTrials.gov